A clinical trial examining MOTS-c was updated on July 8, 2026. The study, registered as NCT07678073, is titled "Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation."
The trial's current status is listed as recruiting. Its phase is designated as not applicable, indicating this study does not fall under the standard phase classification used for drug trials.
According to the registry entry, the study aims to compare two anesthesia approaches, general anesthesia and combined spinal-epidural anesthesia, in the context of renal transplantation. The listed measures of interest include ferroptosis, humanin, and MOTS-c levels. No outcome data or results have been posted as part of this update.
MOTS-c remains classified as an unapproved compound used only in a research context. This trial update reflects registration and recruitment status only, not findings or conclusions about MOTS-c's role in anesthesia or transplantation outcomes.
Further details about the trial's design, eligibility criteria, and methodology can be found in the official registry listing.
For more background on this compound, see the linked compound overview.